Tumor Immune Microenvironment in Lung Cancer
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".
Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 2983
Special Issue Editor
Interests: lung cancer; immune regulation; cytokine signaling; gene regulation; dendritic cells; in situ vaccination; immunotherapy; cellular therapies for lung cancer
Special Issue Information
Dear Colleagues,
Lung tumorigenesis, which is often associated with tobacco smoking, is a multistage process driven by the progressive accumulation of both genetic and epigenetic alterations in oncogenes and tumor suppressor genes. In addition, studies reveal that the tumor immune microenvironment plays a key role in the initiation and progression of lung cancer, leading to the recognition that lung cancer is a process of constant and intimate interplay between transformed tumor cells and the tumor microenvironment (TME). The TME contains extracellular matrix, vascular and lymphatic networks, cancer-associated fibroblasts and infiltrating host immune cells, which are intimately intertwined during every step of tumorigenesis. Tumor cells can exert strong immunosuppression on host immune effectors to escape immunosurveillance, while immune cells can either facilitate tumor eradication or promote an immunosuppressive TME favoring tumor progression. Enhanced understanding of the critical components and immunological pathways within the TME has led to the discovery of novel immunotherapies and biomarkers of response that have revolutionized the treatment of lung cancer.
This Special Issue is devoted to the research area of the TME in lung cancer, with the objective of bringing in the most advanced knowledge to provide a comprehensive view of the lung TME as a valuable resource for both basic and translational researchers. We seek high-quality, original research and review papers on topics that include, but are not limited to: cellular components of the TME and their functions in lung tumorigenesis; the metabolic and epigenetic regulations; mechanisms of immunosuppression; advances in technologies to study the lung TME; novel therapeutic strategies to overcome the immunosuppressive TME; and biomarkers of response and resistance to therapies targeting the lung TME.
Dr. Bin Liu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung cancer
- tumor microenrivonment
- immunosuppression
- response and resistance
- immunotherapy
- cancer metabolism
- epigenetics
- therapeutic strategy
